Mirae Asset Global Etfs Holdings Ltd. Trevi Therapeutics, Inc. Transaction History
Mirae Asset Global Etfs Holdings Ltd.
- $43.4 Billion
- Q1 2025
A detailed history of Mirae Asset Global Etfs Holdings Ltd. transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Mirae Asset Global Etfs Holdings Ltd. holds 44,143 shares of TRVI stock, worth $277,659. This represents 0.0% of its overall portfolio holdings.
Number of Shares
44,143
Previous 33,698
31.0%
Holding current value
$277,659
Previous $143,000
93.71%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding TRVI
# of Institutions
142Shares Held
85.3MCall Options Held
1.5MPut Options Held
304K-
Nea Management Company, LLC Timonium, MD11.4MShares$71.5 Million6.78% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$64.5 Million4.06% of portfolio
-
Rubric Capital Management LP New York, NY4.54MShares$28.5 Million0.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.84MShares$24.1 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.49MShares$21.9 Million5.95% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $367M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...